This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, ...

Hims & Hers Health has seen massive success, aided by the growing use of GLP-1 drugs. Click here to find out why I downgrade ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Hims to cut 4% of workforce amid ban on weight ... cancer risks Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related cancers ...

Telehealth platform Hims & Hers is set to acquire UK startup Zava to strengthen its international presence. Meanwhile, ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

To sustain momentum, Hims recently announced a deal with Novo Nordisk A/S (NYSE: NVO) to distribute branded Wegovy at ...

US telehealth group explores selling ‘compounded medications’ in new markets after buying London-based rival Zava ...

Telemedicine company Hims & Hers has hired Farshad Shadloo to lead communications. As VP of communications, Shadloo reports to Khobi Brooklyn, chief corporate affairs officer at Hims & Hers, he wrote ...

Tuesday, online health and wellness company Hims & Hers announced its intent to acquire European digital healthcare provider ...